Assenagon Asset Management S.A. lowered its holdings in Voyager Therapeutics, Inc. (NASDAQ:VYGR – Get Rating) by 17.8% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 16,224 shares of the company’s stock after selling 3,517 shares during the quarter. Assenagon Asset Management S.A.’s holdings in Voyager Therapeutics were worth $96,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Price T Rowe Associates Inc. MD raised its stake in shares of Voyager Therapeutics by 1,735.8% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 827,950 shares of the company’s stock worth $4,893,000 after buying an additional 782,850 shares during the last quarter. Millennium Management LLC raised its stake in shares of Voyager Therapeutics by 291.0% during the 2nd quarter. Millennium Management LLC now owns 828,796 shares of the company’s stock worth $4,898,000 after buying an additional 616,814 shares during the last quarter. Walleye Capital LLC acquired a new position in shares of Voyager Therapeutics during the 1st quarter worth $1,148,000. Renaissance Technologies LLC acquired a new position in shares of Voyager Therapeutics during the 2nd quarter worth $557,000. Finally, Goldman Sachs Group Inc. raised its stake in shares of Voyager Therapeutics by 241.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 113,560 shares of the company’s stock worth $865,000 after buying an additional 80,277 shares during the last quarter. Institutional investors and hedge funds own 59.58% of the company’s stock.
Voyager Therapeutics Trading Up 0.4 %
Voyager Therapeutics stock opened at $9.24 on Thursday. The stock has a market cap of $356.73 million, a PE ratio of -20.09 and a beta of 0.92. The stock has a 50-day moving average price of $6.33 and a 200 day moving average price of $6.22. Voyager Therapeutics, Inc. has a 52 week low of $2.60 and a 52 week high of $10.81.
Analysts Set New Price Targets
Separately, StockNews.com raised Voyager Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, November 14th.
Insider Buying and Selling at Voyager Therapeutics
In other Voyager Therapeutics news, major shareholder Ecor1 Capital, Llc sold 110,000 shares of Voyager Therapeutics stock in a transaction dated Wednesday, January 11th. The stock was sold at an average price of $8.50, for a total value of $935,000.00. Following the completion of the sale, the insider now owns 3,851,507 shares in the company, valued at approximately $32,737,809.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 22.00% of the stock is owned by company insiders.
About Voyager Therapeutics
Voyager Therapeutics, Inc is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. Its pipeline of gene therapy programs includes VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guang Ping Gao, Mark A.
- Get a free copy of the StockNews.com research report on Voyager Therapeutics (VYGR)
- Procter & Gamble Earnings: A Gamble Worth Taking
- Stocks Slide, Economic Report Paints Gloomy Picture For Economy
- What does Nu Holdings Stock Have To Do With Warren Buffett?
- J.B. Hunt Gets A Flat, Logistic Companies Come Into Focus
- Is Intel Stock On The Verge Of Breaking Out?
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.